NEXGEL, Inc. Stock

NXGL

US65344E1073

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-24 EDT			5-day change	1st Jan Change
0.4390 ^USD	+2.09%		-6.87%	-72.73%

07-02	Nexgel, Inc. Announces Resignation of Scott Henry as Member of Board of Directors, Effective July 1, 2026	CI
05-19	NEXGEL, Inc. Reports Positive Data From Randomized Single-Center IRB Study To Evaluate The Effectiveness And Safety Of A Hydrogel Laser Treatment Patch In Laser Hair Removal	CI

Last Transcript: NEXGEL, Inc.

NEXGEL, Inc., Q1 2026 Earnings Call, May 15, 2026

05-15

More transcripts

Managers and Directors: NEXGEL, Inc.

Manager	Title	Age	Since
Adam Levy CEO	Chief Executive Officer	63	2019-09-09
Ian Blackman DFI	Director of Finance/CFO	58	2026-04-26
Gregory J. Robb COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Jerome Zeldis BRD	Director/Board Member	76	2020-03-31
Kevin Harris BRD	Director/Board Member	55	2026-05-05
Steven Ciardiello BRD	Director/Board Member	55	2025-07-30

More insiders

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Companyâ€™s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-24	US$0.4390	+2.09%	14,120
26-07-23	US$0.4300	+4.62%	26,445
26-07-22	US$0.4110	-5.58%	48,574
26-07-21	US$0.4353	-2.29%	49,151
26-07-20	US$0.4455	-5.49%	24,910

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.4390USD

Average target price

2.000USD

Spread / Average Target

+355.58%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	4.01M 3.52M 3.27M 3M 5.65M 386M 5.73M 38.88M 15.19M 190M 15.05M 14.72M 656M	P/E 2026 *	-3.66x	P/E 2027 *	1.1x
Enterprise Value	4.01M 3.52M 3.27M 3M 5.65M 386M 5.73M 38.88M 15.19M 190M 15.05M 14.72M 656M	EV / Sales 2026 *	0.17x	EV / Sales 2027 *	0.12x
Free-Float	86.29%	Yield 2026 *	-	Yield 2027 *	-

07-02	Nexgel, Inc. Announces Resignation of Scott Henry as Member of Board of Directors, Effective July 1, 2026	CI
05-19	NEXGEL, Inc. Reports Positive Data From Randomized Single-Center IRB Study To Evaluate The Effectiveness And Safety Of A Hydrogel Laser Treatment Patch In Laser Hair Removal	CI
05-15	NEXGEL, Inc., Q1 2026 Earnings Call, May 15, 2026
05-14	NEXGEL, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	NEXGEL, Inc. announced that it has received $1.21 million in funding	CI
05-13	Nexgel appoints Dave Hazard as vice president of sales for Bionx Surgical	RE
05-10	NEXGEL, Inc. announced that it expects to receive $1.21 million in funding	CI
05-10	NEXGEL, Inc. announced that it has received $1 million in funding	CI
05-06	Sequence LifeScience, Inc. announced that it has received $5.5 million in funding from NEXGEL, Inc.	CI
05-06	Nexgel, Inc. Appoints Brian J. Kieser and Kevin Harris to Board of Directors	CI
04-27	Nexgel, Inc. Appoints Ian Blackman as Chief Financial Officer	CI
04-21	Nexgel Inc co and Celularity enter amendment no. 1 to license agreement on April 17, 2026	RE
04-21	NEXGEL, Inc., Q4 2025 Earnings Call, Apr 21, 2026

06-05	NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th -18th	AQ
06-04	NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th	AQ
05-19	NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration	AQ
05-13	NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical	AQ
05-12	NEXGEL To Report First Quarter 2026 Financial Results on May 15th	AQ

1 day	+2.09%
1 week	-6.87%
Current month	-12.38%
1 month	-14.71%
3 months	-32.04%
6 months	-73.71%
Current year	-72.73%

1 week	0.4	0.47
1 month	0.4	0.58
Current year	0.4	1.9
1 year	0.4	2.89
3 years	0.4	5.1
5 years	0.4	5.1
10 years	0.4	5.1

NEXGEL, Inc. Stock

Stocks

NXGL

US65344E1073

Pharmaceuticals

Valuation: NEXGEL, Inc.

Chart: NEXGEL, Inc.

Latest news : NEXGEL, Inc.

Last Transcript: NEXGEL, Inc.

Press Releases: NEXGEL, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: NEXGEL, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/23/26	Adam Levy	Sell	Chief Executive Officer	-5,000	0.0548%
6/11/26	Adam Levy	Sell	Chief Executive Officer	-3,000	0.0329%
6/8/26	Adam Levy	Sell	Chief Executive Officer	-3,000	0.0329%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEXGEL, INC.	+2.09%	-6.87%	-81.40%	-79.49%	4.01M
ELI LILLY AND COMPANY	+0.86%	+1.43%	+47.17%	+161.40%	1,067B
JOHNSON & JOHNSON	+1.59%	+4.09%	+56.51%	+52.79%	635B
ABBVIE INC.	+0.95%	+1.91%	+36.30%	+83.13%	458B
ROCHE HOLDING AG	+1.60%	+6.25%	+37.00%	+30.00%	347B
NOVARTIS AG	-0.60%	+1.52%	+36.67%	+39.80%	295B
ASTRAZENECA PLC	-0.14%	+0.60%	+17.29%	+18.19%	262B
NOVO NORDISK A/S	+0.09%	-2.82%	-29.09%	-41.29%	216B
AMGEN INC.	+1.22%	+2.66%	+22.66%	+59.81%	203B
GILEAD SCIENCES, INC.	-1.18%	-3.70%	+11.28%	+67.43%	161B
Average	+0.65%	+0.51%	+15.44%	+39.18%	364.35B
Weighted average by Cap.	+0.76%	+1.95%	+35.99%	+78.15%

	2026 *	2027 *
Net sales	24.06M 21.13M 19.65M 18.03M 33.89M 2.32B 34.41M 233M 91.18M 1.14B 90.33M 88.38M 3.94B	34.13M 29.98M 27.88M 25.58M 48.07M 3.29B 48.81M 331M 129M 1.62B 128M 125M 5.59B
Net income	-976K -857K -797K -732K -1.37M -93.99M -1.4M -9.47M -3.7M -46.21M -3.66M -3.58M -160M	3.85M 3.38M 3.15M 2.89M 5.42M 371M 5.51M 37.36M 14.6M 182M 14.46M 14.15M 631M
Net Debt	-	-